ReShape Lifesciences Insiders
| RSLSDelisted Stock | USD 15.68 3.60 29.80% |
ReShape Lifesciences employs about 17 people. The company is managed by 10 executives with a total tenure of roughly 27 years, averaging almost 2.0 years of service per executive, having 1.7 employees per reported executive. Breaking down ReShape Lifesciences' management performance can provide insight into the firm performance.
| Dan Gladney Chairman Chairman of the Board and Presidentident, CEO |
| Paul Hickey President Senior Vice President - Marketing and Reimbursement |
ReShape |
ReShape Lifesciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.535) % which means that it has lost $0.535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2016) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.ReShape Lifesciences holds 10.62 pct. of its outstanding shares held by insiders and 1.3 pct. owned by third-party entities.
Some institutional investors establish a significant position in stocks such as ReShape Lifesciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of ReShape Lifesciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
ReShape Lifesciences Workforce Comparison
ReShape Lifesciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,247. ReShape Lifesciences claims roughly 17.0 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.65. ReShape Lifesciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ReShape Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ReShape Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ReShape Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ReShape Lifesciences Notable Stakeholders
A ReShape Lifesciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ReShape Lifesciences often face trade-offs trying to please all of them. ReShape Lifesciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ReShape Lifesciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dan Gladney | Chairman of the Board and Presidentident, CEO | Profile | |
| Paul Hickey | Senior Vice President - Marketing and Reimbursement | Profile | |
| Naqeeb Ansari | Senior Vice President - Sales | Profile | |
| MBA DVM | VP Officer | Profile | |
| Al Diaz | Vice RD | Profile | |
| DVM DVM | VP Officer | Profile | |
| Thomas Stankovich | Chief Officer | Profile | |
| Jody Dahlman | Director Communications | Profile | |
| Katherine Tweden | CoFounder | Profile | |
| Mark Knudson | CoFounder CEO | Profile |
About ReShape Lifesciences Management Performance
The success or failure of an entity such as ReShape Lifesciences often depends on how effective the management is. ReShape Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ReShape management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ReShape management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.
Please note, the imprecision that can be found in ReShape Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ReShape Lifesciences. Check ReShape Lifesciences' Beneish M Score to see the likelihood of ReShape Lifesciences' management manipulating its earnings.
ReShape Lifesciences Workforce Analysis
Traditionally, organizations such as ReShape Lifesciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ReShape Lifesciences within its industry.ReShape Lifesciences Manpower Efficiency
Return on ReShape Lifesciences Manpower
| Revenue Per Employee | 470.9K | |
| Revenue Per Executive | 800.6K | |
| Net Loss Per Employee | 419.4K | |
| Net Loss Per Executive | 713K |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in ReShape Stock
If you are still planning to invest in ReShape Lifesciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ReShape Lifesciences' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |